Utilize AlpHelix's bispecific antibody platform to develop novel bispecific therapeutic antibodies from clinically-proven monoclonal antibody medicines:

For example, the bispecific antibodies that show better efficacy than current anti-PD-1 antibodies and other anti-tumor monoclonal antibodies (e.g. PD-1xHer2, PD1xEGFR, PD1xcMET, etc.)

1.Through the dual specificity of tumor targets and PD-1 targets on T cells, bispecific antibodies can gather T cells into the tumor microenvironment;

2.By bridging tumor cells and T cells, bispecific antibodies can increase the cytotoxicity of T cells on tumor cells.